News

Promising year for TB patients
Enlarge image

RegulatoryFranceGermanyEU

Promising year for TB patients

07.01.2013 - The new year could be particularly beneficial for tuberculosis patients. Two new drugs are expected to be approved by the EMA.

After almost 50 years without new treatments against tuberculosis, 2013 might give patients better options. Both Otsuka Pharma from Japan, as well as Johnson & Johnson's German affiliate Janssen-Cilag GmbH, have ongoing approval procedures for the drugs Delamanid and Bedaquilin, respectively. Bedaquilin was approved by the US regulatory authority FDA at the beginning of the new year. The expected European approvals of both medicines by the European Medicines Agency (EMA) are based on Phase II clinical data with Phase III trials continuing in parallel.  

Also in Phase II, are another two drugs against TB developed by Bayer from Germany and Sanofi from France. However, both substances – Moxifloxacin (yet approved for other indications) and Rifapentin (also already approved by the FDA) – have not entered European approval procedures yet.  

Tuberculosis is mainly spread in Eastern Europe and developing countries but it is also considered an recurring threat for Western Europe. The German Association for Research-Based Pharmaceutical Companies, VFA, estimates that about one third of the earth's population carries the pathogen. Disease outbreaks normally only occur in vulnerable patients following infections by, for example, HIV. Although in general curable, TB has its caveats when compared with other infections of the respiratory tract. Killing mycobacteria without any resistances takes about half a year and comes with nasty side effects. Additionally, many strains have acquired multiple resistances which makes new and better treatment options desirable. That's why the Innovative Medicines Initiative has launched a R&D programme aimed to find better treatments last summer. According to the VFA, some of the upcoming drugs have new modes of actions which makes them especially valuable when mixing different substances for combination therapies. Bedaquilin is the first substance to interfere with energy production of the mycobacteria, while Moxifloxacin is the first to inhibit DNA replication. 

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-01/promising-year-for-tb-patients.html

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%

FLOP

  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%

TOP

  • 4SC1.18 EUR71.0%
  • MEDIGENE12.90 EUR63.9%
  • FORMYCON31.00 EUR31.1%

FLOP

  • MORPHOSYS60.74 EUR-13.0%
  • BB BIOTECH281.20 EUR-11.2%
  • EPIGENOMICS5.31 EUR-10.6%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%

FLOP

  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 18.04.2015